Free Trial

Organovo (ONVO) Short Interest Ratio & Short Volume

Organovo logo
$0.35 0.00 (0.00%)
(As of 11:50 AM ET)

Organovo Short Interest Data

Organovo (ONVO) has a short interest of 145,300 shares. This marks a 271.61% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.2, indicating that it would take 2.2 days of the average trading volume of 366,816 shares to cover all short positions.

Current Short Interest
145,300 shares
Previous Short Interest
39,100 shares
Change Vs. Previous Month
+271.61%
Dollar Volume Sold Short
$65,719.19
Short Interest Ratio
2.2 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
15,370,000 shares
Percentage of Shares Shorted
0.95%
Today's Trading Volume
39,111 shares
Average Trading Volume
366,816 shares
Today's Volume Vs. Average
11%
Short Selling Organovo?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Organovo and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ONVO Short Interest Over Time

ONVO Days to Cover Over Time

ONVO Percentage of Float Shorted Over Time

Organovo Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/2024145,300 shares $65,719.19 +271.6%N/A2.2 $0.45
10/15/202439,100 shares $16,910.75 +20.3%N/A0.6 $0.43
9/30/202432,500 shares $16,542.50 -12.9%N/A0.3 $0.51
9/15/202437,300 shares $20,216.60 -57.2%N/A0.4 $0.54
8/31/202487,100 shares $50,518.00 -38.4%N/A0.9 $0.58
8/15/2024141,400 shares $78,901.20 +22.6%N/A1.2 $0.56
7/31/2024115,300 shares $64,568.00 +44.1%N/A0.8 $0.56
7/15/202480,000 shares $54,240.00 -18.7%N/A0.5 $0.68
6/30/202498,400 shares $74,990.64 -10.1%N/A0.1 $0.76
6/15/2024109,400 shares $99,094.52 -25.6%N/A0.1 $0.91
5/31/2024147,100 shares $144,628.72 -57.0%N/A0.1 $0.98
5/15/2024342,300 shares $352,569.00 -16.7%N/A0.3 $1.03
4/30/2024410,700 shares $439,449.00 +174.4%N/A0.4 $1.07
4/15/2024149,700 shares $202,095.00 -7.5%N/A0.2 $1.35
3/31/2024161,900 shares $166,757.00 +19.6%N/A1.5 $1.03
3/15/2024135,400 shares $142,170.00 -10.0%N/A1.1 $1.05
2/29/2024150,400 shares $153,408.00 -63.1%N/A0.9 $1.02
2/15/2024407,000 shares $415,140.00 +29.4%N/A2.3 $1.02
1/31/2024314,600 shares $320,892.00 -15.5%N/A1.4 $1.02
1/15/2024372,300 shares $394,638.00 +9.0%N/A1.7 $1.06
12/31/2023341,600 shares $379,176.00 +117.4%N/A1.6 $1.11
12/15/2023157,100 shares $174,381.00 -54.4%N/A0.8 $1.11
11/30/2023344,400 shares $402,948.00 -22.5%N/A2.2 $1.17
11/15/2023444,100 shares $675,032.00 +2.4%N/A3.9 $1.52
10/31/2023433,700 shares $459,722.00 +7.6%N/A5.8 $1.06
10/15/2023403,200 shares $495,936.00 -2.6%N/A10.6 $1.23
9/30/2023414,000 shares $517,500.00 -2.8%N/A10.7 $1.25
9/15/2023426,000 shares $566,580.00 +7.1%N/A11 $1.33
8/31/2023397,600 shares $477,120.00 +8.0%N/A14.1 $1.20
8/15/2023368,000 shares $563,040.00 +2.3%N/A14.3 $1.53
7/31/2023359,900 shares $601,033.00 -21.4%N/A15.2 $1.67
7/15/2023458,000 shares $792,340.00 +3.3%N/A18.8 $1.73
6/30/2023443,600 shares $749,684.00 -2.3%N/A19.7 $1.69
6/15/2023453,800 shares $821,378.00 +2.9%N/A19.1 $1.81
5/31/2023441,200 shares $750,040.00 +13.1%N/A15.4 $1.70
5/15/2023390,200 shares $721,870.00 -10.1%N/A9.7 $1.85
4/30/2023434,000 shares $846,300.00 +4.4%N/A3.9 $1.95
4/15/2023415,900 shares $885,867.00 +10.3%N/A3.6 $2.13
3/31/2023377,200 shares $826,068.00 +21.0%N/A3.2 $2.19
3/15/2023311,800 shares $595,538.00 +6.9%N/A2.7 $1.91
Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

2/28/2023291,600 shares $691,092.00 -11.1%N/A2.6 $2.37
2/15/2023327,900 shares $865,656.00 +21.7%N/A3.1 $2.64
1/31/2023269,400 shares $439,122.00 -10.5%N/A5.3 $1.63
1/15/2023300,900 shares $553,656.00 -0.6%N/A12.9 $1.84
12/30/2022302,700 shares $426,807.00 +1.7%N/A13.3 $1.41
12/15/2022297,800 shares $530,143.56 -2.8%N/A13.9 $1.78
11/30/2022306,400 shares $462,664.00 -1.7%N/A12.3 $1.51
11/15/2022311,600 shares $511,024.00 +1.4%N/A4.4 $1.64
10/31/2022307,400 shares $504,136.00 -2.9%N/A4.1 $1.64
10/15/2022316,600 shares $541,386.00 -4.7%N/A4 $1.71
9/30/2022332,100 shares $680,805.00 -2.1%N/A3.8 $2.05
9/15/2022339,200 shares $783,552.00 +41.0%N/A2.3 $2.31
8/31/2022240,500 shares $567,580.00 -1.0%N/A1.6 $2.36
8/15/2022243,000 shares $738,720.00 -21.3%N/A2.4 $3.04
7/31/2022308,800 shares $907,872.00 -11.6%N/A3.2 $2.94
7/15/2022349,400 shares $946,874.00 +14.2%N/A3.7 $2.71
6/30/2022306,000 shares $541,620.00 -6.2%N/A3.5 $1.77
6/15/2022326,100 shares $658,722.00 +6.7%N/A13 $2.02
5/31/2022305,500 shares $736,255.00 -2.6%N/A12.3 $2.41
5/15/2022313,600 shares $799,680.00 +2.4%N/A9.7 $2.55
4/30/2022306,400 shares $879,368.00 +0.8%N/A8.5 $2.87
4/15/2022303,900 shares $1.00 million -1.9%N/A8 $3.30
3/31/2022309,800 shares $1.16 million -2.2%N/A6.9 $3.76
3/15/2022316,600 shares $1.21 million -6.0%N/A5.4 $3.83
2/28/2022336,800 shares $1.20 million -0.5%N/A5.3 $3.56
2/15/2022338,600 shares $1.03 million -3.4%N/A5.6 $3.04
1/31/2022350,600 shares $1.09 million +3.3%N/A5.2 $3.12
1/15/2022339,500 shares $1.27 million -0.4%N/A5 $3.74
12/31/2021340,900 shares $1.24 million +96.9%N/A5.2 $3.63
12/15/2021173,100 shares $718,365.00 +30.1%N/A3 $4.15
11/30/2021133,100 shares $637,549.00 +38.1%N/A2.4 $4.79
11/15/202196,400 shares $526,344.00 +0.7%N/A1.8 $5.46
10/29/202195,700 shares $594,297.00 -34.9%N/A1.6 $6.21
10/15/2021147,100 shares $950,266.00 -49.5%N/A2.6 $6.46
9/30/2021291,300 shares $1.98 million -11.2%N/A5.1 $6.80
9/15/2021328,100 shares $2.44 million +1.8%N/A4.8 $7.44
8/31/2021322,400 shares $2.47 million -36.5%N/A4 $7.66
8/13/2021507,700 shares $3.96 million +1.4%N/A2.2 $7.80
7/30/2021500,900 shares $3.84 million -11.5%N/A2.1 $7.67
7/15/2021565,800 shares $4.26 million -7.2%N/A2.3 $7.53
6/30/2021609,600 shares $5.73 million -11.6%N/A2.3 $9.40
6/15/2021689,200 shares $5.71 million +39.0%N/A2.6 $8.28
5/28/2021496,000 shares $4.66 million -0.7%7.1%1.8 $9.40
5/14/2021499,600 shares $3.32 million -1.4%7.2%2.5 $6.65
4/30/2021506,700 shares $4.48 million +8.6%7.3%1.7 $8.85
4/15/2021466,700 shares $4.31 million +5.1%6.7%1.5 $9.24
3/31/2021444,100 shares $4.05 million -3.8%6.4%1.3 $9.13
3/15/2021461,600 shares $5.42 million -9.7%6.6%1.1 $11.74
2/26/2021511,400 shares $6.54 million +90.8%7.3%1.2 $12.78
2/12/2021268,100 shares $5.82 million -23.6%3.8%0.7 $21.70
Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

1/29/2021351,000 shares $4.61 million +4.1%5.0%1.2 $13.13
1/15/2021337,200 shares $4.96 million -7.9%4.8%1.3 $14.72
12/31/2020366,200 shares $4.86 million +100.1%5.6%1.5 $13.26
12/15/2020183,000 shares $1.36 million -31.0%2.8%0.9 $7.43
11/30/2020265,300 shares $2.39 million +10.5%4.0%2 $9.00
11/15/2020240,000 shares $2.21 million -3.4%3.6%1.9 $9.19
10/30/2020248,500 shares $2.34 million +20.1%3.8%1.9 $9.41
10/15/2020207,000 shares $1.98 million +42.4%3.2%1.6 $9.58
9/30/2020145,400 shares $1.15 million +45.0%2.3%1.5 $7.91
9/15/2020100,300 shares $766,292.00 -19.2%1.6%1.3 $7.64
8/31/2020124,100 shares $1.13 million -90.9%1.9%1.6 $9.12
8/14/20201,370,000 shares $19.33 million +12.3%21.3%18.6 $14.11
7/31/20201,220,000 shares $16.08 million -11.6%1.0%0.7 $13.18
7/15/20201,380,000 shares $17.80 million +12.2%1.1%0.8 $12.90
6/30/20201,230,000 shares $13.53 million -6.8%1.0%0.8 $11.00
6/15/20201,320,000 shares $14.93 million -16.5%1.0%0.9 $11.31
5/29/20201,580,000 shares $19.96 million -31.6%1.2%1.1 $12.63
5/15/20202,310,000 shares $26.49 million -31.5%1.8%1.7 $11.47
4/30/20203,370,000 shares $28.52 million +19.9%2.6%4.3 $8.46
4/15/20202,810,000 shares $17.74 million +33.8%2.2%4.4 $6.31
3/31/20202,100,000 shares $777,000.00 -8.2%1.6%3.1 $0.37
3/13/20202,286,300 shares $731,616.00 +14.9%1.8%5.7 $0.32
2/28/20201,990,000 shares $437,800.00 +8.2%1.5%3.2 $0.22
2/14/20201,840,000 shares $515,200.00 +58.6%1.4%2.9 $0.28
1/31/20201,160,000 shares $324,800.00 -26.6%0.9%1.7 $0.28
1/15/20201,580,000 shares $553,000.00 +6.8%1.2%2.2 $0.35
12/31/20191,480,000 shares $547,600.00 -25.6%1.2%2.2 $0.37

ONVO Short Interest - Frequently Asked Questions

What is Organovo's current short interest?

Short interest is the volume of Organovo shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 145,300 shares of ONVO short. Learn More on Organovo's current short interest.

What is a good short interest ratio for Organovo?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ONVO shares currently have a short interest ratio of 2.0. Learn More on Organovo's short interest ratio.

Is Organovo's short interest increasing or decreasing?

Organovo saw a increase in short interest in October. As of October 31st, there was short interest totaling 145,300 shares, an increase of 271.6% from the previous total of 39,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Organovo's short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Organovo: MIRA Pharmaceuticals, Inc. (12.65%), Pieris Pharmaceuticals, Inc. (1.70%), GlycoMimetics, Inc. (8.75%), Enlivex Therapeutics Ltd. (0.75%), Spruce Biosciences, Inc. (0.56%), Cyclo Therapeutics, Inc. (0.69%), Unity Biotechnology, Inc. (1.97%), MEI Pharma, Inc. (1.23%), ProPhase Labs, Inc. (0.65%), Flora Growth Corp. (9.66%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Organovo stock?

Short selling ONVO is an investing strategy that aims to generate trading profit from Organovo as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Organovo?

A short squeeze for Organovo occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ONVO, which in turn drives the price of the stock up even further.

How often is Organovo's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONVO, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:ONVO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners